Literature DB >> 3559292

Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B.

G Fattovich, S Boscaro, F Noventa, E Pornaro, D Stenico, A Alberti, A Ruol, G Realdi.   

Abstract

Serological markers of hepatitis delta virus (HDV) infection were found in 18 (12%) of 146 consecutive patients with chronic hepatitis B, and the characteristics of patients who had antibody to HDV (anti-HDV-positive) were analyzed. During one to 15 years of follow-up, histological deterioration was documented in 77% of anti-HDV-positive patients; however, in hepatitis B surface antigen (HBsAg) carriers without HDV infection, histology deteriorated in 30% but improved or remained unchanged in the majority of patients (P less than .01). In seven (70%) of the 10 anti-HDV-positive patients who showed transition from chronic active hepatitis to cirrhosis, this event was observed within the first two years of follow-up. The probability of evolution to cirrhosis was significantly higher in anti-HDV-positive patients than in patients without antibody to HDV (P less than .001). These findings indicate that HDV infection in patients with chronic hepatitis B is associated with a more-rapid progression to cirrhosis compared with HBsAg carriers with chronic hepatitis and no evidence of HDV infection.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3559292     DOI: 10.1093/infdis/155.5.931

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  48 in total

Review 1.  Hepatitis delta virus: A fascinating and neglected pathogen.

Authors:  Celso Cunha; João Paulo Tavanez; Severin Gudima
Journal:  World J Virol       Date:  2015-11-12

Review 2.  Epidemiology, Natural History, and Treatment of Hepatitis Delta Virus Infection in HIV/Hepatitis B Virus Coinfection.

Authors:  Nicole D Ferrante; Vincent Lo Re
Journal:  Curr HIV/AIDS Rep       Date:  2020-08       Impact factor: 5.071

3.  Establishment of a novel quantitative hepatitis D virus (HDV) RNA assay using the Cobas TaqMan platform to study HDV RNA kinetics.

Authors:  Ingmar Mederacke; Birgit Bremer; Benjamin Heidrich; Janina Kirschner; Katja Deterding; Thomas Bock; Karsten Wursthorn; Michael P Manns; Heiner Wedemeyer
Journal:  J Clin Microbiol       Date:  2010-03-29       Impact factor: 5.948

4.  Human CD4+ T-cell response to hepatitis delta virus: identification of multiple epitopes and characterization of T-helper cytokine profiles.

Authors:  R Nisini; M Paroli; D Accapezzato; F Bonino; F Rosina; T Santantonio; F Sallusto; A Amoroso; M Houghton; V Barnaba
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

5.  Prevalence of Hepatitis B and Hepatitis D Virus Infections in the United States, 2011-2016.

Authors:  Eshan U Patel; Chloe L Thio; Denali Boon; David L Thomas; Aaron A R Tobian
Journal:  Clin Infect Dis       Date:  2019-08-01       Impact factor: 9.079

6.  Hepatitis D Virus: A Call to Screening.

Authors:  Joseph Ahn; Robert G Gish
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-10

7.  A new bioassay for terbinafine.

Authors:  M Häuser; H J Schmitt; E M Bernard; D Armstrong
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-08       Impact factor: 3.267

8.  Production of hepatitis delta virus and suppression of helper hepatitis B virus in a human hepatoma cell line.

Authors:  J C Wu; P J Chen; M Y Kuo; S D Lee; D S Chen; L P Ting
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

9.  Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling.

Authors:  Jeremie Guedj; Yaron Rotman; Scott J Cotler; Christopher Koh; Peter Schmid; Jeff Albrecht; Vanessa Haynes-Williams; T Jake Liang; Jay H Hoofnagle; Theo Heller; Harel Dahari
Journal:  Hepatology       Date:  2014-10-27       Impact factor: 17.425

Review 10.  Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead.

Authors:  Heiner Wedemeyer; Michael P Manns
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-01       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.